F8 and hemophilia A: The FF curve height of the CWA-TT in the mixing test with normal and FVIII-deficient plasma was convex on top, independent of the presence of emicizumab, whereas that with plasma from a hemophilia A patient with an inhibitor treated with emicizumab and FVIII-deficient plasma showed a convex, decreasing pattern (Figure 4b).